Fresenius ups profit forecast on strong growth in generic drugs

Frankfurt

GERMAN healthcare group Fresenius on Wednesday toned up its earnings guidance for the year as demand for recently launched generic infusion drugs continued to grow at higher-than-expected rates.

For 2017, it now expects adjusted net income to grow by 19 to 21 per cent, excluding the effect of currency swings, compared with a previous target for a 17 to 20 per cent gain, to be shored up later this year by market launches of more than 10 products that have lost patent protection.